Research

Hormonal

Preclinical evidence suggests GLP-1 receptor agonists may offer cardioprotective benefits beyond weight loss, such as reducing fibrosis and inflammation, but this remains unproven in humans.

Current human trials show GLP-1 benefits are mostly due to weight loss. However, animal studies suggest the drug might also directly reduce heart inflammation and fibrosis. This potential direct benefit is not yet proven in humans, so patients should focus on the proven weight loss benefits while researchers investigate these additional mechanisms.

LimitedQualifiesLOW confidence
Apart from improving glycaemic control and exercise capacity, semaglutide-treated mice showed an overall improvement in cardiac performance by reduction in natriuretic peptide levels, inflammatory responses, fibrosis as well as attenuated left ventricular hypertrophy... To date, only one study compared the effects of GLP-1RA with caloric restriction in cardiometabolic HFpEF [55&&].
Federico Capone et al. · Current Opinion in Cardiology · 2024

Why this rating

Based on preclinical mouse models, not human clinical trials.

Source

Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF

Federico Capone et al. · Current Opinion in Cardiology · 2024

DOI 10.1097/hco.0000000000001117

narrative_reviewCited 13×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →